BC Extra | Apr 2, 2019
Financial News

Ocular oncology play Aura raises $40M D round

Medicxi led a $40 million series D round for Aura as the ocular oncology company prepares its lead choroidal melanoma therapy for Phase III testing in 1H20. The funding will give Aura Biosciences Inc. (Cambridge,...
BC Week In Review | Dec 22, 2017
Financial News

Aura raises $30M series C

Aura Biosciences Inc. (Cambridge, Mass.) raised $30 million in a series C round led by new investors Lundbeckfonden Ventures and Arix Bioscience plc. Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital,...
BC Extra | Dec 21, 2017
Financial News

Aura raises $30M series C

Aura Biosciences Inc. (Cambridge, Mass.) raised $30 million in a series C round led by new investors Lundbeckfonden Ventures and Arix Bioscience plc. Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital,...
BC Week In Review | Apr 26, 2017
Clinical News

AU-011: Ph Ib started

Aura began an open-label, U.S. Phase Ib trial to evaluate single injections of 2 dose levels of intravitreal AU-011 in up to 12 patients. Aura Biosciences Inc. , Cambridge, Mass.  Product: AU-011   Business: Cancer  Molecular...
Items per page:
1 - 4 of 4